10 January 2019 - The PBAC considered many submissions for new cancer medicines (new medicine, new indication and new combination product) in 2018.

Insofar as some submissions included a request for more than one patient population and/or medicine, the number of outcomes are greater than the number of submissions.

In the end, the PBAC published 47 outcomes:

• 11 for a new medicine
  
• 34 for a new indication
  
• 2 for a new combination product
  

A further two submissions (new indication) were withdrawn.

25 of the 47 outcomes were recommendations (53%). The recommendation rate for all submissions in 2018 was 67%.